Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Amgen Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net income (loss) 627 2,830 746 (113) 767 1,730 1,379 2,841 1,616 2,143 1,317 1,476 1,899 1,884 464 1,646 1,615 2,021 1,803 1,825
Depreciation, amortization and other 1,397 1,396 1,400 1,399 1,380 895 896 900 911 837 828 841 852 850 855 841 873 901 930 897
Stock-based compensation expense 134 136 157 103 161 104 119 47
Deferred income taxes (334) (110) (383) (401) (623) (447) (154) (49) (351) (333) (263) (251) (189) (127) (46) (91) 52 (78) (177) (84)
Acquired in-process research and development 1,505
Adjustments for equity method investments 1 28 (12) (27) 28 (14) 28 (31) 178 216 192 305 (97) 166 49 (85)
Loss on divestiture 2 5 560
(Gains) losses on equity securities 876 (1,633) 401 515 (261) (135) 661 (1,830) 14 (209) 111 211
Other items, net (9) 68 28 (95) (16) 574 65 (60) (25) 9 85 29 22 (149) 42 164 (135) 25 138 107
Noncash adjustments to reconcile net income (loss) to net cash provided by operating activities 2,065 (115) 1,591 1,494 669 977 1,615 (1,023) 729 525 1,513 1,135 588 740 2,405 829 790 848 891 920
Trade receivables, net 473 (342) (176) 486 (433) (342) (96) (144) (180) (62) (309) (195) (160) (304) (56) 91 (396) 1,146 (222) (955)
Inventories 323 681 722 806 573 (54) 30 (58) (91) (241) (180) (230) 50 (48) (41) (126) 101 (90) (113) (113)
Other assets (14) (299) (250) (89) (232) (263) 70 (139) 92 (32) 241 (43) 136 (115) (112) (146) 65 (79) (176) 319
Accounts payable (232) (122) 643 23 (187) 156 (118) (253) 296 (44) (140) 42 191 (104) (127) (29) 247 14 (191) (25)
Accrued income taxes, net 53 247 (1,534) 223 (2,029) 527 28 443 (155) 193 (1,003) 318 (135) 211 (982) 52 52 (753) 315 137
Long-term tax liabilities 69 76 78 (715) 78 97 89 107 44 77 51 57 102 55 (22) 69 (592) 4 32 74
Accrued liabilities 728 (275) 693 (1,054) 884 (282) 581 (230)
Accrued sales incentives and allowance 658 929 (77) (316) 520 242 575 (402)
Other liabilities 21 (39) 23 (56) (72) (28) (44) (78) 298 419 440 (396) 137 99 402 (282) 271 257 503 (48)
Changes in operating assets and liabilities, net of acquisitions 2,079 856 122 (692) (898) 53 1,115 (754) 304 310 (900) (447) 321 (206) (938) (371) (252) 499 148 (611)
Net cash provided by operating activities 4,771 3,571 2,459 689 538 2,760 4,109 1,064 2,649 2,978 1,930 2,164 2,808 2,418 1,931 2,104 2,153 3,368 2,842 2,134
Purchases of marketable securities (1) (224) (387) (1,976) 1 (901) (403) (7,597) (3,148) (3,100) (2,100) (129)
Proceeds from sales of marketable securities (2) 1 1,124 98 (1) 405 3,999 (1) 24 2,574
Proceeds from maturities of marketable securities 550 673 400 15 32 904 1,399 3,004 3,524 2,043 2,100 125 113
Purchases of property, plant and equipment (371) (257) (238) (230) (249) (248) (271) (344) (340) (160) (246) (190) (287) (242) (185) (166) (173) (135) (158) (142)
Cash paid for acquisitions, net of cash acquired (26,989) (3,839) (890) (13) (1,626)
Other (31) 47 21 13 151 (13) 59 28 159 (120) 14 47 42 (169) 14 (79) (106) (492) (50) (2,646)
Net cash (used in) provided by investing activities (402) (210) (217) (217) (27,089) (262) (211) 1,358 (3,473) (267) (2,193) (111) (230) 73 1,209 (319) (1,384) (1,628) (2,159) (230)
Net proceeds from issuance of debt 3,996 1 (18) 23,798 (19) 2,984 2 3,952 (1) 4,946 (88) 4,039 4,963
Extinguishment of debt (249) (410) (97) (130) (420) (297)
Repayment of debt (2,200) (1,400) (750) (704) (4,150) (1,450) (1,750) (3,250)
Repurchases of common stock (200) (6,360) (1,443) (1,080) (1,581) (871) (1,205) (765) (555) (961)
Dividends paid (1,205) (1,210) (1,209) (1,208) (1,140) (1,140) (1,139) (1,137) (1,040) (1,038) (1,038) (1,080) (990) (999) (1,008) (1,016) (932) (936) (942) (945)
Other (2) 8 (40) (90) (5) 14 (53) (28) 10 (61) (26) (26) 26 (19) (33) (52) (3) (9) (17) (61)
Net cash provided by (used in) financing activities (1,407) (3,651) (2,649) (1,708) 2,754 (2,005) (1,210) 21,509 (1,049) 1,588 (1,062) (3,514) (6,558) 2,848 (2,622) (1,939) (3,590) (1,798) 775 (254)
Increase (decrease) in cash and cash equivalents 2,962 (290) (407) (1,236) (23,797) 493 2,688 23,931 (1,873) 4,299 (1,325) (1,461) (3,980) 5,339 518 (154) (2,821) (58) 1,458 1,650

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Amgen Inc. net cash provided by operating activities increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Amgen Inc. net cash (used in) provided by investing activities increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Amgen Inc. net cash provided by (used in) financing activities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 exceeding Q2 2024 level.